Lupin

Lupin FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Lupin (LUPIN.NS) as of Oct 11, 2026 is 96.29 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 40.15 % — a change of 139.84% (higher).

FCF Conversion

96.29 %

YoY

139.84%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Lupin is 2026 96.29 % . FCF Conversion Rate (FCF/EBITDA) of Lupin was 2025 40.15 % . It decreases by 139.84% higher compared to the previous year.

The Lupin FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2019
112.21 INR
Jan 1, 2020
-295.37 INR
Jan 1, 2021
94.05 INR
Jan 1, 2022
35.19 INR
Jan 1, 2023
92.39 INR
Jan 1, 2024
142.05 INR
Jan 1, 2025
40.15 INR
Jan 1, 2026
96.29 INR
The Lupin FCF Conversion history
YEARFCF ConversionYoY
96.29 %+139.84%
40.15 %-71.74%
142.05 %+53.74%
92.39 %+162.53%
35.19 %-62.58%
94.05 %-131.84%
-295.37 %-363.23%
112.21 %+42.56%
78.71 %+36.32%
57.74 %-121.09%
-273.83 %-453.46%
77.47 %+26.20%
61.39 %—
Access this data via the Eulerpool API
Get Free API Key

Lupin Stock analysis

What does Lupin do? Lupin Limited is an Indian pharmaceutical company specializing in generics and novel therapies. It was founded in 1968 by Dr. Desh Bandhu Gupta and has experienced rapid growth, becoming one of the leading companies in the global pharmaceutical market. The company's business model involves manufacturing and marketing generics and novel therapies for the treatment of various diseases such as cancer, diabetes, cardiovascular diseases, and respiratory diseases. Lupin operates worldwide with a wide range of partners to distribute its products in over 100 countries. The company is involved in various divisions including generics, novel therapies, biosimilars, and inhalation products. Lupin's generics division encompasses a wide range of products such as antibiotics, antidepressants, antihypertensives, and many other categories. Its novel therapies include innovative products for the treatment of diabetes, cancer, multiple sclerosis, and other chronic diseases. Lupin is also involved in the development of biosimilars, which are imitation biopharmaceuticals manufactured using living organisms. Lastly, the company offers inhalation products for the treatment of respiratory diseases such as asthma and COPD. Lupin has built an impressive product pipeline over the years, having submitted over 174 ANDA applications (for the approval of new generics) to the US FDA and introduced more than 80 new products in the Indian market. It has also established an innovative research and development center that focuses on the discovery of new molecules and the development of new therapeutic approaches. Another important feature of Lupin is its commitment to quality and sustainability. The company has received numerous awards for its product quality and environmental initiatives. In 2019, Lupin received the Sustainable Business Award from CNBC TV18. Overall, Lupin Limited is a successful and fast-growing company specializing in generics and novel therapies. It has a wide range of products and an impressive pipeline, and operates globally. Due to its commitment to quality and sustainability, Lupin Limited has also built a strong reputation among its customers and partners. Lupin is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Lupin stock

FCF Conversion Rate (FCF/EBITDA) of Lupin is 96.29 % in 2026.

FCF Conversion Rate (FCF/EBITDA) of Lupin changed from 40.15 % to 96.29 %, representing a 139.84% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Lupin since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Lupin with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API
Get Free API Key

Cash Flow — Lupin

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — Lupin